Cohort characteristics
| . | Postinduction (N = 38) . | Relapsed/refractory (N = 25) . |
|---|---|---|
| Age, median (range), y | 55 (41-68) | 58 (44-75) |
| Time since MM diagnosis, median (range) | 222 d (76-783) | 4.6 y (1.8-14.5) |
| High-risk cytogenetic features, % | 40 (only 20 with available data) | 96 |
| Lines of prior MM therapy, median (range) | 1 (1-4) | 7 (3-13) |
| Prior treatment exposure, median (range), % | ||
| Thalidomide, lenalidomide, or pomalidomide | 76 | 100 |
| Proteasome inhibitor | 55 | 100 |
| Alkylating agent | 21 | 100 |
| High-dose chemotherapy + ASCT | N/A* | 92 |
| Bone marrow cellularity occupied by MM at time of enrollment, median (range), % | 13 (0-80) | 65 (0-95) |
| . | Postinduction (N = 38) . | Relapsed/refractory (N = 25) . |
|---|---|---|
| Age, median (range), y | 55 (41-68) | 58 (44-75) |
| Time since MM diagnosis, median (range) | 222 d (76-783) | 4.6 y (1.8-14.5) |
| High-risk cytogenetic features, % | 40 (only 20 with available data) | 96 |
| Lines of prior MM therapy, median (range) | 1 (1-4) | 7 (3-13) |
| Prior treatment exposure, median (range), % | ||
| Thalidomide, lenalidomide, or pomalidomide | 76 | 100 |
| Proteasome inhibitor | 55 | 100 |
| Alkylating agent | 21 | 100 |
| High-dose chemotherapy + ASCT | N/A* | 92 |
| Bone marrow cellularity occupied by MM at time of enrollment, median (range), % | 13 (0-80) | 65 (0-95) |
MM, multiple myeloma; N/A, not applicable.
Patients in the postinduction cohort underwent leukapheresis prior to ASCT.